Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Sachs Immuno-Oncology BD&L Investment Forum 2016
32 slides from Aethlon Medical's conference presentation, Jun 3, 2016
Slide 1: Aethlon Medical, Sachs Immuno-Oncology BD&L Investment Forum
A e thlon Medical, Inc . Nasdaq : AEMD SACHS IMMUNO - ONCOLOGY BD&L INVESTMENT FORUM JUNE 3, 2016 Jim Joyce Chairman, CEO
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced ; market acceptance of the A e thlon ADAPT™ and ELLSA
Slide 3: Immunotherapeutic Technologies to Combat Infectious Disease & Cancer
IMMUNOTHERAPEUTIC TECHNOLOGIES TO COMBAT INFECTIOUS DISEASE & CANCER
Slide 4: Tumor-Derived Exosomes: A Basis for Therapeutic and Diagnostic Partnering
TUMOR - DERIVED EXOSOMES A Basis for Therapeutic and Diagnostic Partnering
Slide 5: Initiated tumor-derived exosome research in 2006
Initiated tumor - derived exosome research in 2006 Considered c ellular debris w ith n o b iological f unction
Slide 6: Tumor-derived exosomes are significant therapeutic and diagnostic targets
2016 Tumor - derived exosomes are significant therapeutic and diagnostic targets
Slide 7: Tumor-Derived Exosomes
Tumor - Derived Exosomes
Slide 8: A Significant Unmet Medical Need in Cancer
Tumor - Derived Exosomes A Significant Unmet Medical Need in Cancer • The seeds of cancer metastasis – The mystery of the Soil & Seed Theory of 1889 • Tumor - derived exosomes promote: – Tumorigenesis – Cancer progression – Angiogenesis – Immune - evasion – Resistance to radiation and chemotherapeut
Slide 9: The Aethlon Hemopurifier
The A e thlon Hemopurifier® Broad - s pectrum e limination of circulating viruses, bacterial toxins and tumor - derived exosomes
Slide 10: Deployed Within the Global Infrastructure of Dialysis & CRRT Machines
DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES
Slide 11: The Aethlon Hemopurifier: FDA approved IDE study
The A e thlon Hemopurifier® FDA approved IDE study currently being conducted
Slide 12: The Hemopurifier Mechanism of Action
The Hemopurifier ® Mechanism of Action • Rapid separation of disease targets from the circulatory blood path • Capture of disease targets through adherence to immune - evasion structure – Lectin - affinity attachment to high - mannose structure that cloaks exosome and pathogen targets from immune su
Slide 13: Previous Human Treatment Experiences
Previous Human Treatment Experiences
Slide 14: HIV/AIDS Patient
HIV/AIDS Patient Average viral load reductions > 50% observed during 4hr treatments
Slide 15: Hepatitis C Virus (HCV)
Hepatitis C Virus (HCV)
Slide 16: HCV Treatment Summary
HCV Treatment Summary • Demonstrated successful use in interferon - based cure strategy • Up to 300 billion HCV copies captured during single six - hour treatments
Slide 17: Ebola Virus
Ebola Virus
Slide 18: Hemopurifier therapy administration to a comatose Ebola patient
Hemopurifier® therapy administration to a comatose Ebola patient with multiple - organ failure
Slide 19: Dr. Stefan Büttner Holding Hemopurifier After Ebola Treatment
Dr. Stefan Büttner Holding Hemopurifier® After Ebola Treatment
Slide 20: Ebola Treatment Data Presented by Dr. Helmut Geiger
Ebola Treatment Data Presented By Dr. Helmut Geiger American Society of Nephrology Annual Meeting • 6.5 hour Hemopurifier® therapy administration • Pre - treatment viral load: 400,000 copies/ml • Post - treatment viral load: 1,000 copies/ml • 242 million of Ebola viruses captured • Patient recovered
Slide 21: Top Best Inventions / Most Remarkable Advances in Healthcare
“Top 25 Best Inventions” “11 Most Remarkable Advances in Healthcare”
Slide 22: In Vitro Hemopurifier Validations
In Vitro Hemopurifier ® Validations • Viruses – Hepatitis C, HIV, Ebola, H1N1 Swine Flu, H5N1 Bird Flu, 1918 Spanish Flu (reconstructed), Monkey Pox, West Nile Virus, Chikungunya and Dengue • Viral Toxins • Ebola glycoprotein ( gp ), HIV gp120, HIV NEF - exosomes • Bacterial Toxins • L ipopolysaccha
Slide 23: Expansive Exosome IP Portfolio
Expansive Exosome IP Portfolio Issued & Pending Patents Teach • Therapeutic elimination of exosomes • Isolation of exosomes from bodily fluids – p latform to diagnose and monitor cancer • Exosome harvesting – exosomal delivery of biologic & chemotherapeutic agents
Slide 24: Partnering/Collaboration Initiatives
Partnering/Collaboration Initiatives
Slide 25: Partnering/Collaboration Initiatives
Partnering/Collaboration Initiatives • Therapeutic elimination of exosomes – Preclinical Hemopurifier - d rug study validations • Confirm combination Hemopurifier - drug synergies • Demonstrate non - affinity binding of drug agent • Expand potential therapeutic indications – Clinical program initiat
Slide 26: Partnering/Collaboration Initiatives
Partnering/Collaboration Initiatives • Therapeutic elimination of exosomes • Isolation of exosomes from bodily fluids – p latform to diagnose and monitor cancer • Exosome harvesting – Exosomal delivery of biologic & chemotherapeutic agents
Slide 27: ELLSA: Proprietary broad-spectrum exosome isolation platform
ELLSA™ (Enzyme - linked lectin - specific assay) Proprietary broad - spectrum exosome isolation platform
Slide 28: Partnering/Collaboration Initiatives
Partnering/Collaboration Initiatives • Isolation of exosomes from bodily fluids – ELLSA co - development partnerships • ELLSA isolation + antibody step to diagnose and monitor specific disease indications • Urine based proof - of - principal established in HIV
Slide 29: Partnering/Collaboration Initiatives
Partnering/Collaboration Initiatives • Therapeutic elimination of exosomes • Isolation of exosomes from bodily fluids – p latform to diagnose and monitor cancer • Exosome harvesting – Exosomal delivery of biologic & chemotherapeutic agents – Contact management to initiate discussions
Slide 30: Immunotherapeutic Technologies to Combat Infectious Disease & Cancer
IMMUNOTHERAPEUTIC TECHNOLOGIES TO COMBAT INFECTIOUS DISEASE & CANCER
Slide 31: Tumor-Derived Exosomes: A Basis for Therapeutic & Diagnostic Partnering
Tumor - Derived Exosomes A Basis for Therapeutic & Diagnostic Partnering
Slide 32: Contact: Aethlon Medical, Inc
CONTACT: A e thlon Medical, Inc 9635 Granite Ridge Drive Suite 100 San Diego, California 92123 Jim Joyce Chairman & CEO jj@aethlonmedical.com 858.459.7800 x301
Aethlon Medical — Sachs Immuno-Oncology BD&L Investment Forum 2016 on 6ix